Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T15:35:59.827Z.
Calculation as of: 2026-10-06T15:35:59.827Z.
Quote observation: 2026-10-06T15:35:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: efaaa36d31f915a5dffaa91b800fc30e2d7f64892a7236e7a1e7b68ff3f7d584
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Crescent Biopharma, Inc.
Market Cap
$525.22M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$524.20M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$522.16M
Operating Cash Flow Yield
N/A
TTM Avg
536.71%
3Y Avg
536.71%
5Y Avg
536.71%
Market Cap
$514.28M
Operating Cash Flow Yield
0.27%
TTM Avg
0.34%
3Y Avg
0.34%
5Y Avg
0.34%
Market Cap
$537.69M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$538.58M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$510.83M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$539.69M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$540.95M
Operating Cash Flow Yield
3.62%
TTM Avg
3.98%
3Y Avg
3.57%
5Y Avg
3.57%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Crescent Biopharma, Inc. (CBIO) | $525.22M | N/A | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $524.20M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $522.16M | N/A | 536.71% | 536.71% | 536.71% |
| 908 Devices Inc. (MASS)vs › | $514.28M | 0.27% | 0.34% | 0.34% | 0.34% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $537.69M | N/A | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $538.58M | N/A | N/A | N/A | N/A |
| Allogene Therapeutics, Inc. (ALLO)vs › | $510.83M | N/A | N/A | N/A | N/A |
| ProKidney Corp. (PROK)vs › | $539.69M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $540.95M | 3.62% | 3.98% | 3.57% | 3.57% |
| Oculis Holding AG (OCS)vs › | $500.37M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
